BMA - Russell County is a medicare approved dialysis facility center in Lebanon, Virginia and it has 10 dialysis stations. It is located in Russell county at 150 E Main Street, Lebanon, VA, 24266. You can reach out to the office of BMA - Russell County at (276) 889-1712. This dialysis clinic is managed and/or owned by Fresenius Medical Care. BMA - Russell County has the following ownership type - Profit. It was first certified by medicare in April, 1994. The medicare id for this facility is 492572 and it accepts patients under medicare ESRD program.
| Name | BMA - Russell County |
|---|---|
| Location | 150 E Main Street, Lebanon, Virginia |
| No. of Dialysis Stations | 10 |
| Medicare ID | 492572 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 150 E Main Street, Lebanon, Virginia, 24266 | |
| (276) 889-1712 | |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago
| NPI Number | 1255435020 |
| Organization Name | Bma Russell County |
| Doing Business As | Bio-medical Applications Of Virginia, Inc. |
| Address | 150 E Main St Lebanon, Virginia, 24266 |
| Phone Number | (540) 889-1712 |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 23 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 4 |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 51 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 461 |
| Percentage of adult patients getting regular hemodialysis at the center | 92 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at BMA - Russell County with elevated calcium levels.
| Patients with hypercalcemia | 51 |
| Hypercalcemia patient months | 461 |
| Patients with Serumphosphor | 55 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 19 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 25 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 34 |
| Patients with Serumphosphor greater than 7 mg/dL | 15 |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 32 |
| Patient months included in arterial venous fistula and catheter summaries | 253 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 53 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 19 |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 33 |
| Hospitalization Rate in facility | 202.6 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 391.1 |
| Hospitalization Rate: Lower Confidence Limit | 110.5 |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at BMA - Russell County were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 35.1 |
| Readmission Rate: Lower Confidence Limit | 9.2 |
News Archive
Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases - kidney, liver and lung fibrosis - the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
ARCA biopharma, Inc. today announced that it has submitted a study protocol for review under the U.S. Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the safety and efficacy of GencaroTM, in approximately 3,000 patients with chronic heart failure who have the genotype that appears to respond most favorably to Gencaro. Gencaro is the Company's investigational, pharmacologically unique beta-blocker and mild vasodilator.
Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
› Verified 6 days ago